Referencias Dekkers C Wheeler D C Sjstrm C

Referencias Dekkers, C. , Wheeler, D. C. , Sjöström, C. D. , Stefansson, B. V. , Cain, V. , & Heerspink, H. (2018). Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3 b-4 chronic kidney disease. Feng, M. , Lv, H. , Xu, X. , Wang, J. , Lyu, W. , & Fu, S. (2019). Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Fioretto, P. , Giaccari, A. , & Sesti, G. (2015). Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT 2) inhibitor, in diabetes mellitus. Heerspink, H. J. , Johnsson, E. , Gause-Nilsson, I. , Cain, V. A. , & Sjöström, C. D. (2016). Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Liakos, A. , Karagiannis, T. , Bekiari, E. , Boura, P. , & Tsapas, A. (2015). Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Müller-Wieland, D. , Kellerer, M. , Cypryk, K. , Skripova, D. , Rohwedder, K. , Johnsson, E. , Garcia-Sanchez, R. , Kurlyandskaya, R. , Sjöström, C. D. , Jacob, S. , Seufert, J. , Dronamraju, N. , & Csomós, K. (2018). Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Sun, Y. N. , Zhou, Y. , Chen, X. , Che, W. S. , & Leung, S. W. (2014). The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.